Philadelphia-negative myeloproliferative neoplasms among Kuwaiti Nationals

被引:0
|
作者
Alshemmari, Salem [1 ]
Almazyad, Mazyad [2 ]
Alwehaib, Aisha [2 ]
Ameen, Reem [3 ]
机构
[1] Fac Med, Dept Med, Safat, Kuwait
[2] Kuwait Univ, Fac Med, Safat, Kuwait
[3] Fac Allied Hlth, Dept Med Lab Sci, Safat, Kuwait
来源
CANCER MEDICINE | 2021年 / 10卷 / 01期
关键词
driver mutations; epidemiology; Myeloproliferative neoplasms; WORLD-HEALTH-ORGANIZATION; TYROSINE KINASE JAK2; MYELOID NEOPLASMS; 2016; REVISION; MUTATION; CLASSIFICATION; EPIDEMIOLOGY; PREVALENCE; DISORDERS; SURVIVAL;
D O I
10.1002/cam4.3633
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The epidemiology, genetics, and thrombosis risk of MPNs among Arabs are largely unknown. This may be attributed to scarce epidemiological data, particularly from our region. Our study included 381 Kuwaiti nationals with Ph-negative MPNs and a confirmed driver mutation involving JAK2 (exon 12 14), CALR, or MPL. This first regional study examines the demographics, clinical parameters, and thrombosis-related attributes of the participants. This study reported a median age of 58 years, with females and males representing 54.9% and 45.1%, respectively. ET was the most frequent subtype of Ph-negative MPNs in our population, accounting for 52.0% of the cases, followed by PV, found in 34.6% of the participants, and PMF, found in 8.4% of participants. The crude annual cumulative incidence of Ph-negative MPNs in Kuwait ranged from 0.674 to 3.177 per 100,000 population across the study period. The most common driver mutation was JAK2V617F, with a frequency of 89.5%. At diagnosis, 19.2% of the patients presented with unexplained thrombosis, and almost half were of arterial origins. Males were more likely to present with arterial thrombosis than females (61.5% vs. 35.3%), whereas venous thrombotic events were more common in females than in males (47.1% vs. 17.9%; p-value = 0.025). Ph-negative MPNs in Kuwait are rare; however, thrombosis is a frequent complication, being documented in up to 19.2% of cases at presentation, more commonly at arterial sites. These findings call for thorough evaluation of patients with unexplained derangements in their hematological parameters during follow-ups.
引用
收藏
页码:365 / 371
页数:7
相关论文
共 50 条
  • [21] Evolving Therapeutic Strategies for the Classic Philadelphia-Negative Myeloproliferative Neoplasms
    Kaplan, Jason B.
    Stein, Brady L.
    McMahon, Brandon
    Giles, Francis J.
    Platanias, Leonidas C.
    [J]. EBIOMEDICINE, 2016, 3 : 17 - 25
  • [22] Proliferative characteristics of Philadelphia-negative myeloproliferative neoplasms - clinical implications
    Sefer, D.
    Bizic-Radulovic, S.
    Kraguljac-Kurtovic, N.
    Bogdanovic, A.
    Cokic, V.
    Miljic, P.
    Beleslin-Cokic, B.
    Knezevic, V.
    Mitrovic-Ajtic, O.
    Lekovic, D.
    Gotic, M.
    [J]. INTERNATIONAL JOURNAL OF LABORATORY HEMATOLOGY, 2017, 39 (01) : 21 - 31
  • [23] Philadelphia-negative myeloproliferative neoplasms as disorders marked by cytokine modulation
    Cacemiro, Maira da Costa
    Cominal, Jucara Gastaldi
    Tognon, Raquel
    Nunes, Natalia de Souza
    Simoes, Belinda Pinto
    de Figueiredo-Pontes, Lorena Lobo
    Bazzo Catto, Luiz Fernando
    Traina, Fabiola
    Souto, Elizabeth Xisto
    Zambuzi, Fabiana Albani
    Frantz, Fabiani Gai
    de Castro, Fabiola Attie
    [J]. HEMATOLOGY TRANSFUSION AND CELL THERAPY, 2018, 40 (02) : 120 - 131
  • [24] Interferon Alfa in the Treatment of Philadelphia-Negative Chronic Myeloproliferative Neoplasms
    Hasselbalch, Hans Carl
    Kiladjian, Jean-Jacques
    Silver, Richard T.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (18) : E564 - E565
  • [25] Aspirin in Philadelphia-Negative Myeloproliferative Neoplasms: What Is the Optimal Dose ?
    Ajzenberg, Nadine
    Faille, Dorothee
    Huisse, Marie-Genevieve
    Anh Hong Cung
    Lamrani, Lamia
    Dumontier, Nicolas
    Jandrot-Perrus, Martine
    Cassinat, Bruno
    Chomienne, Christine
    Dosquet, Christine
    [J]. BLOOD, 2014, 124 (21)
  • [26] Circulating YKL-40 in Philadelphia-negative myeloproliferative neoplasms
    Krecak, Ivan
    Gveric-Krecak, Velka
    Lapic, Ivana
    Roncevic, Pavle
    Gulin, Josipa
    Fumic, Ksenija
    Krecak, Filip
    Holik, Hrvoje
    Durakovic, Nadira
    [J]. ACTA CLINICA BELGICA, 2021, 76 (01) : 32 - 39
  • [27] Philadelphia-negative myeloproliferative neoplasms: From origins to new perspectives
    Bartalucci, Niccolo
    Galluzzi, Lorenzo
    [J]. CELLULAR AND MOLECULAR ASPECTS OF MYELOPROLIFERATIVE NEOPLASMS - PT A, 2021, 365 : IX - XX
  • [28] Genomic Profiling of Blast Phase in Philadelphia-Negative Myeloproliferative Neoplasms
    Roncoroni, Elisa
    Feenstra, Jelena D. Milosevic
    Rumi, Elisa
    Pietra, Daniela
    Ferretti, Virginia Valeria
    Bellini, Marta
    Cavalloni, Chiara
    Casetti, Ilaria Carola
    Jager, Roland
    Bogner, Edith
    Ciboddo, Michele
    Zappasodi, Patrizia
    Vanelli, Cristina Picone Laura
    Astori, Cesare
    Kralovics, Robert
    Cazzola, Mario
    [J]. BLOOD, 2017, 130
  • [29] Crizotinib Has Preclinical Efficacy in Philadelphia-Negative Myeloproliferative Neoplasms
    Gurska, Lindsay M.
    Okabe, Rachel
    Schurer, Alexandra
    Tong, Meng Maxine
    Soto, Mark
    Choi, Daniel
    Ames, Kristina
    Glushakow-Smith, Shira
    Montoya, Allison
    Tein, Ellen
    Miles, Linde A.
    Cheng, Haiying
    Hankey-Giblin, Pamela
    Levine, Ross L.
    Goel, Swati
    Halmos, Balazs
    Gritsman, Kira
    [J]. CLINICAL CANCER RESEARCH, 2023, 29 (05) : 943 - 956
  • [30] Myeloproliferative Syndromes Philadelphia-Negative
    Cassinat, Bruno
    Kiladjian, Jean-Jacques
    [J]. HEMATOLOGIE, 2006, 12 : 47 - 50